JP2020522473A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020522473A5 JP2020522473A5 JP2019564917A JP2019564917A JP2020522473A5 JP 2020522473 A5 JP2020522473 A5 JP 2020522473A5 JP 2019564917 A JP2019564917 A JP 2019564917A JP 2019564917 A JP2019564917 A JP 2019564917A JP 2020522473 A5 JP2020522473 A5 JP 2020522473A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- variable domain
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023172090A JP2024012297A (ja) | 2017-05-23 | 2023-10-03 | Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍関連抗原に結合するタンパク質 |
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762510173P | 2017-05-23 | 2017-05-23 | |
| US62/510,173 | 2017-05-23 | ||
| US201762539416P | 2017-07-31 | 2017-07-31 | |
| US201762539396P | 2017-07-31 | 2017-07-31 | |
| US201762539419P | 2017-07-31 | 2017-07-31 | |
| US62/539,419 | 2017-07-31 | ||
| US62/539,396 | 2017-07-31 | ||
| US62/539,416 | 2017-07-31 | ||
| US201762546292P | 2017-08-16 | 2017-08-16 | |
| US201762546296P | 2017-08-16 | 2017-08-16 | |
| US62/546,292 | 2017-08-16 | ||
| US62/546,296 | 2017-08-16 | ||
| US201762552146P | 2017-08-30 | 2017-08-30 | |
| US62/552,146 | 2017-08-30 | ||
| PCT/US2018/034223 WO2018217947A1 (en) | 2017-05-23 | 2018-05-23 | A protein binding nkg2d, cd16 and a tumor-associated antigen |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023172090A Division JP2024012297A (ja) | 2017-05-23 | 2023-10-03 | Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍関連抗原に結合するタンパク質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020522473A JP2020522473A (ja) | 2020-07-30 |
| JP2020522473A5 true JP2020522473A5 (enExample) | 2021-07-26 |
Family
ID=64395887
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019564917A Withdrawn JP2020522473A (ja) | 2017-05-23 | 2018-05-23 | Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍関連抗原に結合するタンパク質 |
| JP2023172090A Pending JP2024012297A (ja) | 2017-05-23 | 2023-10-03 | Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍関連抗原に結合するタンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023172090A Pending JP2024012297A (ja) | 2017-05-23 | 2023-10-03 | Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍関連抗原に結合するタンパク質 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20200157227A1 (enExample) |
| EP (1) | EP3630169A4 (enExample) |
| JP (2) | JP2020522473A (enExample) |
| KR (1) | KR20200010430A (enExample) |
| CN (1) | CN111278455A (enExample) |
| AU (1) | AU2018271930B2 (enExample) |
| BR (1) | BR112019024632A2 (enExample) |
| CA (1) | CA3064714A1 (enExample) |
| IL (1) | IL270803B1 (enExample) |
| MX (1) | MX2019014000A (enExample) |
| WO (1) | WO2018217947A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4491234A3 (en) | 2017-02-08 | 2025-04-09 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| BR112019017197A2 (pt) | 2017-02-20 | 2020-04-14 | Dragonfly Therapeutics, Inc. | proteínas que se ligam a her2, nkg2d e cd16 |
| PE20220278A1 (es) | 2018-02-08 | 2022-02-25 | Dragonfly Therapeutics Inc | Dominios variables de anticuerpos que se dirigen al receptor nkg2d |
| AU2019218125B2 (en) | 2018-02-08 | 2025-03-13 | Dragonfly Therapeutics, Inc. | Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells |
| TW201942134A (zh) | 2018-02-20 | 2019-11-01 | 美商蜻蜓醫療公司 | 結合cd33、nkg2d及cd16之多特異性結合蛋白及使用方法 |
| EA202190468A1 (ru) | 2018-08-08 | 2021-07-06 | Драгонфлай Терапьютикс, Инк. | Мультиспецифические связывающие белки, которые связывают bcma, nkg2d и cd16, и способы их применения |
| KR20250112921A (ko) | 2018-08-08 | 2025-07-24 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| CN114555117A (zh) * | 2019-10-12 | 2022-05-27 | 百奥泰生物制药股份有限公司 | 抗cd20抗体制剂及抗cd20抗体在治疗cd20阳性疾病中的应用 |
| EP4146271A4 (en) | 2020-05-06 | 2024-09-04 | Dragonfly Therapeutics, Inc. | PROTEINS THAT BIND NKG2D, CD16 AND CLEC12A |
| CN114057875B (zh) * | 2020-07-31 | 2023-05-05 | 北京市神经外科研究所 | 抗cd133的单链抗体及其在制备治疗肿瘤的药物中的用途 |
| AU2021357841A1 (en) * | 2020-10-08 | 2023-06-15 | Affimed Gmbh | Trispecific binders |
| PL244438B1 (pl) * | 2020-12-28 | 2024-01-29 | Inst Biochemii I Biofizyki Polskiej Akademii Nauk | Peptyd do stosowania w leczeniu lub zapobieganiu COVID-19 |
| US12377144B2 (en) | 2021-03-03 | 2025-08-05 | Dragonfly Therapeutics, Inc. | Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen |
| CN117580865A (zh) * | 2021-06-29 | 2024-02-20 | 山东先声生物制药有限公司 | Cd16抗体及其应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040038339A1 (en) * | 2000-03-24 | 2004-02-26 | Peter Kufer | Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| DE10261223A1 (de) * | 2002-12-20 | 2004-07-08 | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH | Steigerung der Immunantwort durch Substanzen, welche die Funktion von Natürlichen Killerzellen beeinflussen |
| DOP2006000029A (es) * | 2005-02-07 | 2006-08-15 | Genentech Inc | Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas) |
| JP5591712B2 (ja) * | 2007-12-14 | 2014-09-17 | ノボ・ノルデイスク・エー／エス | ヒトｎｋｇ２ｄに対する抗体とその使用 |
| UY32808A (es) * | 2009-07-29 | 2011-02-28 | Abbott Lab | Inmunoglobulinas como dominio variable dual y usos de las mismas |
| CA2797981C (en) * | 2010-05-14 | 2019-04-23 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
| WO2012020096A1 (en) * | 2010-08-13 | 2012-02-16 | Medimmune Limited | Monomeric polypeptides comprising variant fc regions and methods of use |
| WO2012061558A2 (en) * | 2010-11-04 | 2012-05-10 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
| AU2011325833C1 (en) * | 2010-11-05 | 2017-07-13 | Zymeworks Bc Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| AU2012332021B8 (en) * | 2011-11-04 | 2017-10-12 | Zymeworks Bc Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| EP2794658B1 (en) * | 2011-12-19 | 2017-03-15 | Synimmune GmbH | Bispecific antibody molecule |
| US20140154253A1 (en) * | 2012-07-13 | 2014-06-05 | Zymeworks Inc. | Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs |
| HRP20181717T1 (hr) * | 2012-09-27 | 2018-12-28 | Merus N.V. | Bispecifična igg protutijela kao aktivatori t stanice |
| EP2968520B1 (en) * | 2013-03-14 | 2021-05-12 | MacroGenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor |
| DK3406633T3 (da) * | 2013-07-25 | 2022-03-28 | Cytomx Therapeutics Inc | Multispecifikke antistoffer, multispecifikke aktiverbare antistoffer og fremgangsmåder til anvendelse heraf |
| WO2015109131A2 (en) * | 2014-01-15 | 2015-07-23 | Zymeworks Inc. | Bi-specific cd3 and cd19 antigen-binding constructs |
| DK3126384T3 (da) * | 2014-04-01 | 2021-01-18 | Adimab Llc | Multispecifikke antistofanaloger omfattende en fælles letkæde, og fremgangsmåder til deres fremstilling og anvendelse |
| TWI742423B (zh) * | 2014-05-29 | 2021-10-11 | 美商宏觀基因股份有限公司 | 特異性結合多種癌症抗原的三特異性結合分子和其使用方法 |
| WO2015197598A2 (en) * | 2014-06-27 | 2015-12-30 | Innate Pharma | Multispecific antigen binding proteins |
| AR100680A1 (es) * | 2015-01-26 | 2016-10-26 | Macrogenics Inc | Anticuerpos anti-dr5 y moléculas que comprenden dominios de unión de dr5 de los mismos |
| WO2016146702A1 (en) * | 2015-03-16 | 2016-09-22 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Trispecific binding molecules for treating hbv infection and associated conditions |
| AU2016284866B2 (en) * | 2015-06-23 | 2022-09-29 | Innate Pharma | Multispecific antigen binding proteins |
| WO2017008169A1 (en) * | 2015-07-15 | 2017-01-19 | Zymeworks Inc. | Drug-conjugated bi-specific antigen-binding constructs |
| EP3374389A1 (en) * | 2015-11-13 | 2018-09-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti- nkg2d single domain antibodies and uses thereof |
| EP4491234A3 (en) * | 2017-02-08 | 2025-04-09 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
-
2018
- 2018-05-23 CA CA3064714A patent/CA3064714A1/en active Pending
- 2018-05-23 EP EP18806934.8A patent/EP3630169A4/en active Pending
- 2018-05-23 BR BR112019024632-0A patent/BR112019024632A2/pt unknown
- 2018-05-23 CN CN201880051763.5A patent/CN111278455A/zh active Pending
- 2018-05-23 AU AU2018271930A patent/AU2018271930B2/en active Active
- 2018-05-23 JP JP2019564917A patent/JP2020522473A/ja not_active Withdrawn
- 2018-05-23 MX MX2019014000A patent/MX2019014000A/es unknown
- 2018-05-23 US US16/615,261 patent/US20200157227A1/en active Pending
- 2018-05-23 KR KR1020197037754A patent/KR20200010430A/ko not_active Ceased
- 2018-05-23 WO PCT/US2018/034223 patent/WO2018217947A1/en not_active Ceased
-
2019
- 2019-11-20 IL IL270803A patent/IL270803B1/en unknown
-
2023
- 2023-10-03 JP JP2023172090A patent/JP2024012297A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020522473A5 (enExample) | ||
| JP2020521448A5 (enExample) | ||
| Ma et al. | Bispecific antibodies: from research to clinical application | |
| JP2021098732A5 (enExample) | ||
| JP2021098733A5 (enExample) | ||
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP2021035388A5 (ja) | Ｃａｉｘ、ａｎｏ１、メソテリン、ｔｒｏｐ２またはクローディン−１８．２を標的にする多重特異性結合タンパク質 | |
| JP2020522474A5 (enExample) | ||
| JP2020510653A5 (ja) | Ｃｅａを標的にする多重特異性結合タンパク質 | |
| JP2020103301A5 (enExample) | ||
| RU2007145419A (ru) | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами | |
| JP2020508997A5 (enExample) | ||
| RU2019128134A (ru) | Антитело против gprc5d и молекула, содержащая антитело | |
| JP2020533311A5 (ja) | ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質 | |
| JP2019536430A5 (enExample) | ||
| RU2021110369A (ru) | Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген | |
| CN116396386A (zh) | Cd3抗体及其药物用途 | |
| JPWO2020033702A5 (enExample) | ||
| FI3582806T3 (fi) | Her2:ta, nkg2d:tä ja cd16:ta sitovia proteiineja | |
| RU2019128204A (ru) | Белки, связывающиеся с psma, nkg2d и cd16 | |
| RU2020111554A (ru) | Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген | |
| JP2020531525A5 (enExample) | ||
| RU2013142600A (ru) | Белки, связывающие специфический мембранный антиген простаты, и соответствующие композиции и способы | |
| JPWO2019157366A5 (enExample) | ||
| JP2020507577A5 (enExample) |